Arvinas, Inc.

NASDAQ:ARVN

Biotechnology

Healthcare
$6.77 -1.30%

-$0.10 today

Market cap
$443.01M
Beta
1.75
P/E (TTM)
-2.2
EPS (TTM)
-$3.46
52W Low $6.06High $14.51

Volume 1.09M

Average 0.89M

ARVN Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

Arvinas, Inc.NASDAQ: ARVN

Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026

Deferred revenue falls 63.3% from a year ago

Deferred revenue stood at $51.8M at the end of Q1 FY2026, down 63.3% from a year earlier and down 27.3% from the prior quarter. Over 3 fiscal years it compounded at -31.2% a year.

Context

  • Deferred revenue amounted to 8.0% of total assets at the end of Q1 FY2026, down 6.1 pp from a year earlier.
  • Deferred revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether deferred revenue keeps falling in the next quarterly balance sheet after a -63.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$51.8M-27.3% QoQ
Last fiscal yearDec 2025
$71.3M-54.4% YoY
Year agoMar 2025
$141M-63.3% since
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-63.3%——
1 year-54.4%——
3-year CAGR-31.2%——
5-year CAGR——
10-year CAGR——

Deferred Revenue history

USD · from the balance sheet

Latest · FY2025
71.3M USD
Year-over-year change
-54.4%
4-year CAGR
-23.3%

Deferred Revenue vs competitors

How ARVN compares with its peers on the latest reported figures

  • ARVN's Mar 2026 deferred revenue of $51.8M is the 2nd highest of the 6 companies compared; the peer median is $10.12M.
  • Its year-over-year change of -63.3% is the 4th highest of 6, against a peer median of -53.1%.
  • Deferred revenue amounts to 8.0% of total assets for ARVN, versus a peer median of 3.1%.
ARVN Competitors Peer median
Deferred Revenue for ARVN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
FHTXFoghorn Therapeutics Inc.Mar 2026$52.3M +1.2%+9.6%23.5%
ARVNArvinas, Inc.Mar 2026$51.8M -63.3%-31.2%8.0%
GLUEMonte Rosa Therapeutics, Inc.Mar 2026$33.06M +1.5%—4.5%
CCCCC4 Therapeutics, Inc.Mar 2026$10.12M -53.1%-9.1%3.1%
NRIXNurix Therapeutics, Inc.Aug 2026$8.61M -66.9%-22.4%0.7%
KYMRKymera Therapeutics, Inc.Jun 2026$0 -100.0%-13.4%0.0%
Peer median (excluding ARVN) $10.12M-53.1%-11.2%3.1%

Competitors are the stored peer set for ARVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents108.3M81.3M311.7M100.5M142.9M
Short-term Investments1.39B1.12B949.3M938.9M542.5M
Net Receivables25.7M8M7.2M13.7M6.4M
Inventory00000
Other Current Assets4.5M26.9M12M14.2M8.9M
Total Current Assets1.55B1.24B1.28B1.07B700.7M
Property, Plant & Equipment (Net)16.6M17.8M14M16M13.4M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets12.5M10.8M10.4M8.1M3.8M
Total Non-current Assets29.1M28.6M24.4M24.1M17.2M
Total Assets1.58B1.27B1.3B1.09B717.9M
Account Payables31.3M5.7M17.8M13.4M24.4M
Short-term Debt00000
Tax Payables010.3M700K3.2M0
Deferred Revenue206.2M218.6M163M156.2M71.3M
Other Current Liabilities12.4M18.7M48M22.4M17.5M
Total Current Liabilities261.7M295.1M257.1M229.8M142.5M
Long-term Debt1M1M800K600K400K
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)534.3M405.1M386.2M292M134.3M
Other Non-current Liabilities0000100K
Total Non-current Liabilities538.2M408.8M387.5M299.9M141.6M
Total Liabilities799.9M703.9M644.6M529.7M284.1M
Common Stock0100K100K100K0
Retained Earnings(682.9M)(965.4M)(1.33B)(1.53B)(1.61B)
Accumulated OCI(4.6M)(19.2M)(3.1M)1M1.2M
Other Stockholders Equity00000
Minority Interest00000
Total Equity781.7M564.9M660M561.7M433.8M
Total Debt5M5.5M3.2M9.7M8.9M
Net Debt(103.3M)(75.8M)(308.5M)(90.8M)(134M)

Arvinas, Inc.

NASDAQ:ARVN

Intrinsic Alpha fair value

Locked

Current Price

$6.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.